762P Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase II clinical study

医学 临床终点 内科学 揭穿 人口 卵巢癌 肿瘤科 外科 化疗 临床研究阶段 不利影响 癌症 临床试验 环境卫生
作者
Bing Xia,Wen Jiang,J. Paul Chen,Yun-Fei Chen,Shan Wu,Wenbin Shen,Yaping Tian,Yun-Fei Chen,Xiaohong Chen,Weiqing Wu,Yuguang Ma,Jing Wang,Wei‐Xiang Qi,Zhonghua Wang,Xiangcheng Li,Xingxing Huang,Lin H,Bin Hong,Hebing Zhou
出处
期刊:Annals of Oncology [Elsevier]
卷期号:34: S520-S520
标识
DOI:10.1016/j.annonc.2023.09.1941
摘要

Optimal tumor reduction surgery is crucial for for advanced ovarian cancer (OC) prognosis. Neoadjuvant chemotherapy can increase surgery chances for OC, but the benefit to patients (pts) is limited. PARP inhibitors combined with anti-angiogenic drugs have significant benefits in the first-line maintenance and recurrence treatment of OC. This study aims to evaluate the efficacy and safety of Pamiparib combined with Surufatinib neoadjuvant therapy (NAT) for advanced unresectable OC in the entire population. This is a single-center, single-arm, phase II study following Simon's two-stage design. 20 pts with newly diagnosed unresectable (Fagotti score ≥ 8 or upper abdominal CT score ≥ 3) FIGO III-IV OC were recruited. Enrolled pts will receive NAT with Pamiparib (40 mg bid q3w for 3 cycles) combined with Surufatinib (250mg bid q3w for 2 cycles), followed by interval debulking surgery (IDS) and4 cycles of platinum-containing chemotherapy. The primary endpoint is complete resection rate (R0), and secondary endpoints include objective response rate (ORR), pathologic complete response(pCR) rate, progression-free survival, overall survival, and safety. As of Aug 30, 2023, of the 20 enrolled pts, 16 had completed genetic testing, and 14 were homologous recombination deficiency (HRD) positive, with 9 cases of BRCA1/2 mutations. By Aug 30, 2023, 17 pts completed NAT and IDS with an ORR of 100%. 15 pts achieved R0 surgery (88.24%), and 2 pts achieved R1. All 20 pts were evaluable by GCIG CA125 criteria, and CA125 response was all observed (100%). Grade 3 or 4 treatment-related adverse events that occurred are neutropenia, thrombocytopenia, anemia, and hepatic dysfunction. Pamiparib combined with Surufatinib as a new neoadjuvant "chemotherapy-free" regimen showed extremely high R0 and ORR rates with manageable toxicity profiles. Currently, the experiment is still ongoing and further analysis and reporting of more data will be conducted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HUI821526发布了新的文献求助10
1秒前
柳易槐发布了新的文献求助10
4秒前
绿地土狗完成签到,获得积分10
6秒前
6秒前
lulu完成签到,获得积分10
6秒前
顾矜应助一一采纳,获得10
6秒前
6秒前
MM完成签到,获得积分10
7秒前
7秒前
Gaye发布了新的文献求助10
7秒前
医研丁真完成签到 ,获得积分10
9秒前
9秒前
liutianq完成签到,获得积分10
9秒前
HUI821526完成签到,获得积分10
11秒前
12秒前
STAR_To完成签到,获得积分10
12秒前
裘问薇完成签到,获得积分10
12秒前
一个小柑橘完成签到,获得积分10
13秒前
QxQMDR完成签到,获得积分10
14秒前
嘿嘿江发布了新的文献求助10
14秒前
Diego发布了新的文献求助10
16秒前
牛牛要当院士喽完成签到,获得积分10
17秒前
17秒前
shubido完成签到,获得积分10
18秒前
爆米花应助光亮的世界采纳,获得10
18秒前
烤鸭本鸭完成签到,获得积分10
18秒前
21秒前
呆呆完成签到 ,获得积分10
21秒前
年轻的凤发布了新的文献求助10
21秒前
22秒前
牛牛要当院士喽完成签到,获得积分10
24秒前
star完成签到 ,获得积分10
25秒前
汉堡包应助shubido采纳,获得10
25秒前
Annnn发布了新的文献求助10
26秒前
希望天下0贩的0应助mgh采纳,获得10
28秒前
28秒前
土豪的泥猴桃完成签到,获得积分10
31秒前
acheng发布了新的文献求助10
35秒前
木子发布了新的文献求助20
36秒前
久久完成签到,获得积分10
37秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3140405
求助须知:如何正确求助?哪些是违规求助? 2791283
关于积分的说明 7798359
捐赠科研通 2447650
什么是DOI,文献DOI怎么找? 1301996
科研通“疑难数据库(出版商)”最低求助积分说明 626359
版权声明 601194